The off-patent product business of branded generics has had a long winning streak in China, sustaining years of double-digit growth for companies and driven by some well-established brands. Even when market shares in the US and Europe have eroded greatly, the same products have continued to enjoy healthy growth in China.
But this so-called “long tail” now seems to be near its end in the country.




![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

